Literature DB >> 19802998

The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers.

E R Wise1, G C Armstrong, R M Brown, J M Andrews.   

Abstract

Eight healthy male volunteers received either 1 g of ceftazidime or cefamandole as an intravenous bolus injection. Serial blood samples were taken over the following 8 h. Urine samples were collected over 24 h. Tissue fluid levels of the antibiotics were studied using a cantharides blister technique. Both drugs achieved high serum levels after intravenous injection (ceftazidime 83.3 mg/l, cefamandole 77.7 mg/l at 0.25 h). The serum half-lives were ceftazidime 1.8 h (S.D. 0.22), cefamandole 0.8 h (S.D. 0.07). The mean apparent volume of distribution of ceftazidime was greater than cefamandole (13.6 l compared with 9.8 l, respectively). The total clearance of ceftazidime was 111 ml/min (S.D. 16.6) compared to 216 ml/min (S.D. 30.1) for cefamandole. The maximum concentration of each drug in blister fluid was greater after ceftazidime (44.7 mg/l) than cefamandole (20.2 mg/l). The terminal half-life of ceftazidime in blister fluid (2.1 h) was similar to that in serum but the blister fluid halflife of cefamandole (1.22 h) was slightly prolonged compared with that in serum. suggested that ceftazidime attains levels in this tissue fluid model after a 1 g intravenous dose which might be sufficient to treat infections caused by Staphylococcus aureus, Pseudomonas aeruginosa as well as the common Gram-negatives.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19802998     DOI: 10.1093/jac/8.suppl_b.277

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients.

Authors:  M Jonsson; M Walder
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

2.  The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.

Authors:  R A Walstad; K Dahl; K B Hellum; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  The pharmacokinetics of ceftazidime in lactating and non-lactating cows.

Authors:  R Rule; G H Quiroga; M Rubio; H O Buschiazzo; P M Buschiazzo
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

Review 4.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 5.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

6.  Altered pharmacokinetics of ceftazidime in critically ill patients.

Authors:  C M Gómez; J J Cordingly; M G Palazzo
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.